TITLE

The lighter side of myeloma: an easily overlooked diagnosis

AUTHOR(S)
Spiller, Robin; Feld, J. J.; Guindi, M.; Heathcote, E. J.
PUB. DATE
October 2005
SOURCE
Gut;Oct2005, Vol. 54 Issue 10, p1376
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Presents case report of a 61 year old man who developed back pain, fatigue, and anaemia. Treatment of the patient; Information that IgG K multiple myeloma was diagnosed and the patient was treated with vincristine, adriamycm, and dexamethasone; Questions related to the diagnosis.
ACCESSION #
18457680

 

Related Articles

  • Simultaneous occurrence of two B-cell malignancies: A case report. SHUJUAN ZHOU; YONGYONG MA; LAIXI BI; ZHIJIAN SHEN; KANG YU // Oncology Letters;2014, Vol. 8 Issue 2, p908 

    The present study describes the case of a 75-year-old male with coexisting multiple myeloma and diffuse large B-cell lymphoma. Although the two malignancies are mature B-cell neoplasms, their clinical manifestations are very different and the clinical approaches used to treat these two types of...

  • Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14). Hundemer, M.; Klein, U.; Hose, D.; Raab, M.-S.; Cremer, F. W.; Jauch, A.; Benner, A.; Heiß, C.; Moos, M.; Ho, A. D.; Goldschmidt, H. // Bone Marrow Transplantation;Dec2007, Vol. 40 Issue 11, p1033 

    Lack of CD56 expression was reported to be associated with a poor prognosis in multiple myeloma (MM) patients treated with conventional chemotherapy. Aim of our retrospective study was to analyse whether CD56 expression on MM cells reveals as a prognostic factor in patients treated with...

  • BORTEZOMIB (V) IN COMBINATION WITH DOXIL (D) AND THALIDOMIDE (T) YIELD HIGH RESPONSE RATE IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA. Miller, Kena; Musiali, Laurie // Oncology Nursing Forum;Mar2006, Vol. 33 Issue 2, p438 

    Multiple Myeloma (MM) is an incurable hematologic cancer. all patients (pts) eventually relapse and die of progressive disease. Development of newer therapies and combination regimens are imperative for management of patients with relapsed/refractory disease. While V is approved for MM the...

  • Extramedullary disease and targeted therapies for hematological malignancies—is the association real? P Raanani; O Shpilberg; I Ben-Bassat // Annals of Oncology;Jan2007, Vol. 18 Issue 1, p7 

    During the past years targeted therapies have gained a major role in the treatment of cancer patients, including those with hematological malignancies. Extramedullary involvement is a rare manifestation of acute and chronic leukemias and of multiple myeloma. Nevertheless, with the expanding use...

  • Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Lacy, M. Q.; Hayman, S. R.; Gertz, M. A.; Short, K. D.; Dispenzieri, A.; Kumar, S.; Greipp, P. R.; Lust, J. A.; Russell, S. J.; Dingli, D.; Zeldenrust, S.; Fonseca, R.; Bergsagel, P. L.; Roy, V.; Mikhael, J. R.; Stewart, A. K.; Laumann, K.; Allred, J. B.; Mandrekar, S. J.; Rajkumar, S. V. // Leukemia (08876924);Nov2010, Vol. 24 Issue 11, p1934 

    Patients with multiple myeloma progressing on current therapies have limited treatment options. Pomalidomide (CC4047), an immunomodulatory drug, has significant activity in relapsed myeloma and previous studies suggest activity in lenalidomide refractory disease. To better define its efficacy in...

  • Multiple myeloma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Harousseau, J.-L.; Dreyling, M. // Annals of Oncology;May2008 Supplement 2, Vol. 19 Issue 0, pii55 

    The article presents the clinical recommendations of the European Society for Medical Oncology (ESMO) for the diagnosis, treatment and follow-up of patients with multiple myeloma (MM). Data on the crude incidence and mortality rates of MM in Europe are given. Examples of tests that diagnosis...

  • Doxorubicin liposomal.  // Reactions Weekly;9/18/2004, Issue 1019, p9 

    Discusses research being done on the side effects of antineoplastic therapy with doxorubicin liposomal in an elderly patient with multiple myeloma. Reference to a study by P. Kiewe and colleagues published in the July to August 2004 issue of "Annals of Pharmacotherapy"; Occurrence of ageusia;...

  • High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Gojo, I.; Guo, C.; Sarkodee-adoo, C.; Meisenberg, B.; Fassas, A.; Rapoport, A.; Cottler-fox, M.; Heyman, M.; Takebe, N.; Tricot, G. // Bone Marrow Transplantation;Jul2004, Vol. 34 Issue 1, p69 

    Summary:The purpose of the study was to examine the yield of CD34+ cells, response rates, and toxicity of high-dose cyclophosphamide with or without etoposide in patients with multiple myeloma. In total, 77 myeloma patients received either cyclophosphamide 4.5?g/m2 (n=28) alone or with etoposide...

  • The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma. Braga, Walter M. T.; Atanackovic, Djordje; Colleoni, GiseleW. B. // Clinical & Developmental Immunology;2012, p1 

    The development of multiple myeloma (MM) involves a series of genetic alterations and changes in the bone marrow microenvironment, favoring the growth of the tumor and failure of local immune control. Quantitative and functional alterations in CD4+ and CD8+ T cells have been described in MM. The...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics